BBNX Beta Bionics, Inc.

Nasdaq www.betabionics.com


$ 20.00 $ 0.00 (0 %)    

Thursday, 23-Oct-2025 15:59:46 EDT
QQQ $ 610.63 $ 0.00 (0 %)
DIA $ 467.25 $ 0.00 (0 %)
SPY $ 671.65 $ 0.00 (0 %)
TLT $ 91.44 $ 0.00 (0 %)
GLD $ 378.73 $ 0.00 (0 %)
$ 21.22
$ 21.21
$ 19.95 x 200
$ 20.07 x 4
$ 19.58 - $ 21.21
$ 8.89 - $ 26.66
769,175
na
920.75M
$ 1.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-29-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-25-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Stifel analyst Jonathan Block reinstates Beta Bionics (NASDAQ:BBNX) with a Buy and announces $26 price target.

Core News & Articles

Goldman Sachs analyst David Roman upgrades Beta Bionics (NASDAQ:BBNX) from Neutral to Buy and raises the price target from $...

Core News & Articles

Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from ...

Core News & Articles

Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from ...

Core News & Articles

Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $15 to $17.

Core News & Articles

Beta Bionics (NASDAQ:BBNX) raises FY2025 sales outlook from $82.00 million-$87.00 million to $88.00 million-$93.00 million vs $...

Core News & Articles

Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.47) ...

 sonnet-biotherapeutics-drops-5-intraday-rebounds-14-after-hours-amid-delisting-concerns

Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after...

Core News & Articles

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention t...

Core News & Articles

Truist Securities analyst Richard Newitter initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and announces ...

Core News & Articles

Lake Street analyst Frank Takkinen assumes Beta Bionics (NASDAQ:BBNX) with a Buy rating and announces Price Target of $30.

 goldman-sachs-bullish-on-dexcom-and-insulet-as-diabetes-tech-surges

Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neu...

Core News & Articles

Goldman Sachs analyst David Roman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Neutral rating and announces Price...

Core News & Articles

Wolfe Research analyst Mike Polark initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Outperform rating and announces P...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION